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Abstract 
 
Background and purpose. Purinergic system through the A2A adenosine receptor 
regulates addiction induced by different drugs of abuse. The aim of the present study 
was to investigate the specific role of A2A adenosine receptors in behavioral and 
neurochemical morphine responses related to its addictive properties. 
Experimental approach. Mice lacking A2A adenosine receptors and wild type littermates 
were used to evaluate behavioral responses induced by morphine. Antinociception was 
assessed using the tail-immersion and the hot-plate tests. Place conditioning paradigms 
were used to evaluate the rewarding effects of morphine and the dysphoric responses of 
morphine withdrawal. Microdialysis studies were carried out to evaluate changes in the 
extracellular levels of dopamine in the nucleus accumbens of A2A knockout mice after 
morphine administration. 
Key results. The acute administration of morphine induced a similar enhancement of 
locomotor activity and antinociceptive responses in both genotypes. However, the 
rewarding effects induced by morphine were completely blocked in A2A knockout mice. 
Besides, naloxone did not induce place aversion in animals lacking the A2A adenosine 
receptors.  
Conclusions and implications. Our findings demonstrate the relevant role played by A2A 
adenosine receptors in the addictive properties of morphine. Both, rewarding and 
aversive effects associated to abstinence were abolished in A2A knockout mice, 
supporting a differential role of the A2A adenosine receptor in somatic and motivational 
effects of morphine addiction. This study provides evidence about the role of A2A 
adenosine receptor as a general modulator of the addictive phenomenon.  
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Introduction 
 
Adenosine is an endogenous purine nucleoside, which acts as a neuromodulator 
in the central nervous system (CNS), and regulates a wide range of pathophysiological 
processes, such as epilepsies, sleep disorders, pain, and drug addiction (Hack & 
Christie, 2003). The effects of adenosine are mediated through the activation of four 
receptor types: A1, A2A, A2B and A3 (Fredholm et al., 2005). A2A adenosine receptors are 
found at high concentrations in brain areas involved in the control of motivational 
responses including the olfactory tubercle, the striatum and the nucleus accumbens 
(NAc) (Moreau & Huber, 1999). 
The generation of knockout (KO) mice with complete and specific inactivation 
of the A2A receptor (Ledent et al., 1997) provides a useful genetic model to investigate 
the role of these receptors on addictive processes. We have previously identified that 
A2A gene deletion in mice modifies the behavioral effects induced by different drugs of 
abuse. Thus, nicotine-induced conditioned place preference was suppressed in A2A KO 
mice (Castañé et al., 2006). Additionally, both rewarding and aversive effects of Δ9-
tetrahydrocannabinol were reduced, whereas the expression of rimonabant-precipitated 
Δ9-tetrahydrocannabinol withdrawal was reported to be attenuated in A2A KO mice 
(Soria et al., 2004). Besides, the reinforcing effects of cocaine decreased in these 
mutants in the self-administration paradigm (Soria et al., 2006).  
Dopamine (DA) neurotransmission in the mesolimbic system plays a crucial role 
in reward processes and other addictive related behaviors (Koob, 1996; Di Chiara, 
2002). Interestingly, a striatal hypodopaminergic activity was shown in A2A KO mice 
(Dassesse et al., 2001) which could account for the attenuated reward effects induced by 
psychostimulants observed in KO mice. In the striatum, A2A adenosine receptors are 
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expressed on GABAergic striatopallidal neurons and are co-localized with D2 DA 
receptors (Ferré et al., 1997). Adenosine appears to regulate DA neurotransmission 
through antagonistic interactions between adenosine A1/DA D1 receptors and adenosine 
A2A/DA D2 receptors (Franco et al., 2000). 
Interactions between the purinergic and opioid systems have also been reported. 
Thus, A2A adenosine receptors regulate proenkephalin gene expression in the striatum 
(Fink et al., 1992; Schiffmann & Vanderhaeghen, 1993). A reduction of [3H]deltorphin-
I binding to delta receptors and an increase in [3H]Cl-977 binding to kappa receptors 
were observed in the spinal cord of A2A adenosine receptors KO mice (Bailey et al., 
2002) associated with functional changes in opioid antinociception. Interestingly, 
adenosine has been suggested to regulate pharmacological responses induced by 
opioids. Thus, the spinal antinociceptive effects of morphine seem to be mediated, at 
least in part, by the release of endogenous adenosine and subsequent activation of A1 
and A2 receptors (Sweeney et al., 1987; 1991). Adenosine also participates in the 
development of opioid physical dependence since the blockade of adenosine 
metabolism by adenosine kinase inhibitors (Kaplan & Coyle, 1998) and the 
administration of adenosine agonists (Kaplan & Sears, 1996) decrease the severity of 
morphine abstinence, whereas adenosine antagonists increase the expression of 
withdrawal symptoms in rats (Salem & Hope, 1997). In agreement, we have shown that 
the severity of morphine withdrawal was increased in mice lacking A2A adenosine 
receptors (Berrendero et al., 2003; Bailey et al., 2004). However, the involvement of 
A2A adenosine receptors in the motivational effects induced by opioids remains to be 
clarified. 
The aim of the present study was to investigate the specific role of A2A 
adenosine receptors in morphine-induced behavioral and neurochemical responses 
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related to its addictive properties. For this purpose, we have evaluated the acute 
locomotor and antinociceptive effects induced by morphine in mice lacking A2A 
receptors. In addition, the rewarding properties of morphine and the aversive effects 
associated with morphine withdrawal were evaluated in these mutant mice by using the 
place conditioning paradigm.  Finally, in vivo microdialysis studies were performed to 
assess if the acute effects of morphine on the extracellular levels of DA in the NAc were 
modified in these KO animals.  
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Material and Methods 
Animals 
Mice lacking A2A adenosine receptors were generated as previously reported 
(Ledent et al., 1997). In order to homogenize the genetic background of the mice, the 
first generation heterozygotes were bred for 30 generations on a CD1 background 
(Charles River, France) with selection for the mutant A2A gene at each generation. 
Beginning with the 30th generation of backcrossed mice, heterozygote-heterozygote 
matings of A2A KO mice produced wild-type (WT) and KO littermates for subsequent 
experiments. Breeding couples were periodically renovated by crossing heterozygote 
mice with WT CD1 females (Charles River, France) in order to maintain a genetically 
diverse outbred background.  
Fourteen weeks old male A2A KO mice and WT littermates (30-35 g) were housed five 
per cage in temperature (21 ± 1ºC) and humidity (55 ± 10 %) controlled rooms, with a 
12-h light/12-h dark cycle (light between 8:00 AM and 8:00 PM). For the microdialysis 
experiments, animals were housed three per cage.  Food and water were available ad 
libitum during all experiments except during the exposure to the different behavioral 
paradigms. Mice were handled for one week before starting the experiments. Animal 
procedures were conducted in accordance with the guidelines of the UK Animals Act 
1986 (Scientific Procedures), the guidelines of the European Communities Directive 
86/609/EEC regulating animal research and for the behavioral experiments performed in 
the laboratory of Barcelona approved by the local ethical committee (CEEA-PRBB). 
All experiments were performed under blind conditions.  
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Drugs 
Morphine used for behavioral studies was obtained from Ministerio de Sanidad y 
Consumo (Madrid, Spain). Morphine and cocaine for microdialysis experiments were 
purchased in Sigma Chemical Co (Dorset, U.K.). Naloxone, was purchased from Sigma 
Chemical Co. (Barcelona, Spain).  
All the compounds were dissolved in sterile 0.9 % physiological saline.   
 
Acute effects induced by morphine   
Locomotor activity responses induced by an acute subcutaneous (s.c.) injection 
of morphine (5 and 10 mg/kg, s.c.) or vehicle were evaluated by using locomotor 
activity boxes (9 x 20 x 11 cm) (Imetronic, Bordeaux, France). The boxes were 
provided with two lines of photocells, one 2 cm above the floor to measure horizontal 
activity, and the other located 6 cm above the floor to measure vertical activity (rears), 
in a low luminosity environment (5 lux). Mice were habituated to the locomotor cages 
during 30 min for 3 consecutive days. On the day 4, mice were placed in the locomotor 
activity boxes immediately after morphine (5 and 10 mg/kg, s.c.) or vehicle injection, 
and locomotor activity was recorded during 30 min. 
Antinociceptive effects induced by an acute administration of morphine (5 and 
10 mg/kg, s.c.) or vehicle were evaluated 30 min after the injection by using the tail-
immersion test, as previously described (Simonin et al., 1998). The latency to a rapid 
tail-flick in the bath (50 ± 0.5ºC) was registered with a cut-off latency of 15 s in order to 
prevent tissue damage. Subsequently, the hot-plate test (Eddy & Leimbach, 1953) was 
performed 31 min after morphine (5 and 10 mg/kg, s.c.) or vehicle injection in the same 
experimental sequence. A glass cylinder was used to maintain the heated surface of the 
plate, which was kept at a temperature of 52 ± 0.5º C (Columbus Instruments, 
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Columbus Ohio, USA). The nociceptive threshold was evaluated measuring the licking 
and the jumping responses, and a cut-off of 240 s was used to prevent tissue damage. 
 
Morphine-induced conditioned place preference 
 The rewarding effects of morphine were evaluated using the conditioned place 
preference paradigm, as previously described (Maldonado et al., 1997). The apparatus 
consisted of two main square conditioning compartments (15 x 15 x 15 cm), with 
differences in texture and colors, separated by a triangular central area (Matthes et al., 
1996). The light intensity within the conditioning chambers was 30 lux. During the pre-
conditioning phase, drug-naive mice were placed in the middle of the central area and 
had free access to both compartments of the apparatus for 18 min. The time spent in 
each compartment was recorded by computerized monitoring software (Videotrack; 
View Point, Lyon, France). During the conditioning phase, mice received alternating 
injections of morphine (5 or 10 mg/kg, s.c.) or vehicle and were immediately confined 
into one of the two conditioning compartments during 20 min. Three pairings were 
carried out with morphine and three pairings with vehicle on alternate days. Treatments 
were counterbalanced as closely as possible between compartments. Control animals 
received vehicle every day. The post-conditioning phase was conducted exactly as the 
pre-conditioning phase, i.e. free access to each compartment for 18 min.  
 
Conditioned place aversion to morphine withdrawal 
 Dysphoric effects of morphine withdrawal were investigated using the 
conditioned place aversion paradigm, as previously reported (Valverde et al., 1996). 
Naloxone-induced place aversion in morphine-dependent mice was evaluated on the 
same apparatus described for the previous experiment. The pre-conditioning phase (day 
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1) was performed in the same way as in the place preference experiment and animals 
were free of drugs. The day after the pre-conditioning phase was conducted, opioid 
dependence was induced by intraperitoneal (i.p.) administration of increasing doses of 
morphine (from 20 to 100 mg/kg, i.p.) twice a day at 10:00 and 19:00 h during 7 
consequtive days; 20 and 20 mg/kg on day 2; 40 and 40 mg/kg on day 3; 60 and 60 
mg/kg on day 4; 80 and 80 mg/kg on day 5; 100 and 100 mg/kg on day 6, 7 and 8. A 
control group of animals received saline by using the same injection schedule. On day 
7, animals received the morning morphine (100 mg/kg, i.p.) or saline injection, and 2h 
later naloxone (0.05 or 0.1 mg/kg, s.c.) was administered and the animal was confined 
in the corresponding compartment during 15 min. On day 8, 2 h after morphine (100 
mg/kg, i.p.) or saline injection, animals received saline and were then confined in the 
other compartment. On day 9, animals did not receive any treatment. The post-
conditioning phase (day 9) was performed in the same way as in the pre-conditioning 
phase (free access to both compartments of the apparatus during 18 min).  
 
Microdialysis studies 
Surgery  
One day prior to microdialysis, mice were anaesthetized with isofluorane (3.5-
4.5%) and a microdialysis guide cannula (CMA 7, CMA microdialysis, Solna, Sweden) 
was stereotaxically implanted targeting the NAc.  Each animal was placed on a heated 
mat, supported in a stereotaxic frame and a small bore hole drilled in the skull. A 
microdialysis guide cannula was implanted at coordinates relative to bregma and skull 
(anterior-posterior: +1.5 mm, laterial: -0.9 mm, depth: -4.0 mm) targeting the left NAc 
core-shell border.  The cannula was secured to the skull with a single anchor screw and 
dental acrylic cement. Animals were allowed to recover until they regained their 
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righting reflex, and then housed individually for subsequent microdialysis. 
Microdialysis was carried out in freely-moving mice. Animals were equilibrated in a 
locomotor cage (25.4 x 25.4 x 40.64 cm) 1 h prior to the start of microdialysis.  A 
microdialysis probe (CMA/7/7/1) was connected to a microdialysis system (CMA/120) 
and perfused with artificial cerebrospinal fluid (aCSF: NaCl, 145 mM; KCL, 2.8 mM; 
CaCl2, 1.2 mM, MgCl2, 1.2 mM). Under light and brief isofluorane anesthesia the probe 
was gently inserted into the guide cannula. The final depth of the probe relative to the 
skull was -5.0 mm. The probe was perfused with aCSF at a flow rate of 1 μl/min, 
dialysate collected for 2 h and discarded to ensure a stable basal DA level.  
Subsequently, five consecutive dialysate fractions (F3-7) were collected at intervals of 
20 min to monitor basal DA release. Animals were then injected with 0.9% saline (5 
ml/kg, s.c.), morphine (20 mg/kg, s.c.) or cocaine (20 mg/kg, s.c). Sample fractions 
were collected at 20 min intervals for 120 min (F8-13). All sample fractions were 
collected directly into 35 μl of mobile phase (NaH2PO4, 0.05 M; OSA, 0.8 mM; EDTA, 
0.1 mM; methanol 10% (v/v), adjusted to pH 3.3 with orthophosphoric acid) and frozen 
immediately in dry ice.  After the completion of the microdialysis procedure, mice were 
killed by cervical dislocation, the brains were removed and frozen in isopentane with 
dry ice (-20ºC to -30ºC) for verification of probe placement by histological examination. 
Histology 
Coronal cryostat sections (20 μm) were cut from each brain using a cryostat 
(Zeiss Microm 505E). Probe placement was checked visually using hematoxilin and 
eosin histological staining. Only data obtained from animals with correct probe tracts 
were used for analysis. 
Dopamine Analysis 
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DA concentration in the dialysate was determined by high-performance liquid 
chromatography (HPLC) with electrochemical detection. The HPLC system consisted 
of an ESA582 pump, ESA542 refrigerated automatic sampler, ESA5020 screening 
guard cell (E = +400 mV), ESA5014B dual potential coulometric microdialysis cell, 
CoulochemII electrochemical detector (ESA Analytical Ltd, UK) and a Waters 
spherisorb ODS2 (100 mm x 4.6 mm x 5 μm) analytical column (Waters Ltd, UK) 
protected by a guard column (Phenomenex, UK). The mobile phase (see surgery 
section), filtered through a 0.2 μm nylon membrane and degassed, was pumped at a 
flow rate of 1 ml/min.  All reagents used for the mobile phase were of analytical grade.  
DA was detected on a dual porous graphite electrode system (first electrode reduction 
potential E1 = -70 mV, working electrode oxidation potential E2 = +340 mV).  Under 
these conditions DA had a retention time of 9.2 min with a detection limit of 0.2 nM.  
Dialysate DA levels were quantified by external standard curve calibration, using peak 
area for quantification; data were not corrected for probe recovery.   
 
Statistical analysis 
Acute effects of morphine were compared by using two-way ANOVA (genotype 
and treatment as factors of variation) between subjects, followed by one-way ANOVA 
and Dunnet post-hoc comparisons when required. For the conditioned place preference 
and place aversion experiments, paired two-tailed Student's t-tests were made between 
the post-conditioning and pre-conditioning time spent in the drug paired compartment. 
Data from the microdialysis study (as absolute values) were analysed using a three-way 
ANOVA with fraction (F), genotype (G) and treatment (T) as between factors of 
variation. 
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Results 
Acute effects induced by morphine   
 The acute administration of morphine (5 and 10 mg/kg) induced a similar 
enhancement of locomotor activity and antinociceptive responses in the tail-immersion 
and hot-plate tests in both genotypes. Two-way ANOVA revealed treatment effects in 
all the acute responses, but not interaction between treatment and genotype (Table 1). 
One-way ANOVA calculated for ambulatory movements (Fig 1a) showed a significant 
effect of treatment in WT (F [2.29] = 59.414; p < 0.01) and KO mice (F [2.29] = 
19.326; p < 0.01). Post-hoc analysis showed differences in morphine-treated WT and 
KO mice at the dose of 5 (p < 0.01 for WT; p < 0.05 for KO) and 10 mg/kg (p < 0.01 in 
all the cases) when compared to saline-treated mice. One-way ANOVA calculated for 
total horizontal activity (Fig 1b) showed a significant effect of treatment in WT (F 
[2.29] = 26.954; p < 0.01) and KO mice (F [2.29] = 12.541; p < 0.01). Post-hoc analysis 
showed differences in morphine-treated WT and KO mice at the dose of 10 mg/kg (p < 
0.01) when compared to saline-treated mice. One-way ANOVA calculated for vertical 
activity (Fig 1c) showed a significant effect of treatment in WT (F [2.28] = 11.487; p < 
0.01) and KO mice (F [2.29] = 4.188; p < 0.05). Post-hoc analysis showed differences 
in morphine-treated WT mice at the doses of 5 and 10 mg/kg (p < 0.01), as well as in 
morphine-treated KO mice at the dose of 10 mg/kg (p < 0.05) when compared to saline-
treated mice. No difference was revealed between genotypes. 
 The antinociceptive effects of morphine (5 and 10 mg/kg) were evaluated in A2A 
KO mice and WT littermates by using the tail-immersion (tail withdrawal latency) and 
the hot-plate test (licking and jumping responses). Two-way ANOVA for the responses 
in the tail-immersion test reveled a treatment effect, without genotype effect and not 
interaction between treatment and genotype (Table 1). One-way ANOVA calculated for 
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tail withdrawal latencies showed a significant effect of treatment in WT (F [2.28] = 
42.652; p < 0.01) and KO mice (F [2.29] = 21.192; p < 0.05). Post-hoc analysis showed 
differences in morphine-treated WT and KO mice at the doses of 5 (p < 0.05 for KO 
mice; p < 0.01 for WT) and 10 mg/kg (p < 0.01 in both genotypes) when compared to 
saline-treated mice (Fig 2a). Two-way ANOVA calculated for the licking latency in the 
hot-plate test showed a treatment effect, but not interaction between treatment and 
genotype (Table 1). One-way ANOVA showed a significant effect of treatment in KO 
mice (F [2.29] = 5.963; p < 0.01), but not in WT animals (F [2.29] = 3.019; n.s.). Post-
hoc analysis showed differences in morphine-treated KO mice at the dose of 10 mg/kg 
(p < 0.05) when compared to saline-treated mice (Fig 2b). Two-way ANOVA 
calculated for the jumping responses in the hot-plate showed a treatment effect, but not 
genotype effect and not interaction between treatment and genotype (Table 1). 
Subsequent one-way ANOVA showed a significant effect of treatment in WT (F [2.29] 
= 287.530; p < 0.01) and KO mice (F [2.29] = 221.705; p < 0.01). Post-hoc analysis 
showed differences in morphine-treated WT and KO mice at the doses of 5 and 10 
mg/kg (p < 0.01 in all the cases) when compared to saline-treated mice (Fig 2c). 
 
Morphine-induced conditioned place preference 
 Rewarding responses induced by morphine (5 and 10 mg/kg) were evaluated in 
WT and A2A KO mice using the place conditioning paradigm. One-way ANOVA 
revealed a similar time spent in the drug-associated compartment during the pre-
conditioning phase in the different groups (F [5.86] = 1.160; n.s.), ensuring the use of an 
unbiased procedure (Fig 3). A significant rewarding effect of morphine was observed in 
WT at the both doses of morphine used (5 and 10 mg/kg), but not in mice lacking the 
A2A adenosine receptor. Accordingly, WT mice conditioned with 5 (t [1.9] = -6.903, p < 
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0.01) and 10 mg/kg (t [1.11] = -3.186; p < 0.01) of morphine spent significantly more 
time in the drug-associated compartment during the post-conditioning phase than during 
the pre-conditioning phase. In contrast, A2A KO mice receiving 5 and 10 mg/kg of 
morphine spent the same time in the drug-associated compartment during both phases 
(Fig 3). 
 
Naloxone-induced place aversion in morphine-dependent mice 
 Naloxone-induced aversive effects in morphine-dependent mice were measured 
by using the place conditioning paradigm. One-way ANOVA revealed a similar time 
spent in the drug-associated compartment during the pre-conditioning phase in the 
different groups (F [11,153] = 0.233; n.s.), ensuring the use of an unbiased procedure 
(Fig.4). Naloxone 0.1 mg/kg (s.c.) induced a conditioned place aversion in morphine-
dependent WT mice, as revealed by a significant decrease of the time spent in the drug-
associated compartment during the post-conditioning vs. the pre-conditioning phase (t 
[1.13] = 4.410, p < 0.01). In contrast, morphine-dependent A2A KO receiving such a 
dose of naloxone spent the same time in the drug-associated compartment during both 
phases. The administration of a lower dose of naloxone (0.05 mg/kg) did not induce 
aversive responses in morphine-dependent WT nor in KO animals (Fig 4).  
 
 
Absence of morphine-induced effects on extracellular levels of dopamine in the 
nucleus accumbens 
The extracellular levels of DA in the NAc were assessed by microdialysis in 
freely-moving WT and adenosine A2A receptor KO mice (n = 5 for saline-treated WT 
mice, n = 6 for saline-treated KO mice, n = 6 for morphine-treated WT mice, n = 7 for 
morphine-treated KO mice).  Basal extracellular DA levels in the NAc measured over 
  Castañé et al. 
 16
five dialysate fractions (F3-7) were comparable in WT (1.29 ± 0.32 nM, n = 11) and KO 
mice (1.08 ± 0.16 nM, n = 13) (Fig 5; genotype; P = 0.450, n.s.). Administration of 
morphine (20 mg/kg, s.c.) had no effect on extracellular DA levels in the NAc of either 
treated WT or KO mice compared to saline treated groups (Fig 5) despite inducing the 
marked behavioral responses of hyperlocomotion and straub tail (data not shown).  
Further studies using different probe target co-ordinates (left lateral shell of NAc 
anterior-posterior: +0.98 mm, laterial: -1.7 mm, depth: -5.0 mm) or prolonged time 
between microdialysis surgery and the day of the experiment (5 day protocol; day 1, 
implant cannula, day 3, implant probe, day 5, commence experiment) at two doses of 
morphine (10 mg/kg and 20 mg/kg) also failed to show any effect of morphine 
administration on extracellular DA in the NAc of WT or KO mice (data not shown). 
However, under the same experimental conditions, administration of cocaine (20 mg/kg, 
s.c.) to WT and KO mice produced a significant increase in extracellular DA levels in 
the NAc compared to saline-treated groups (treatment; P < 0.001) confirming method 
validation. The maximal increase of accumbal DA induced by cocaine in WT and KO 
mice was comparable between genotypes (268.3 % and 293.3 %, respectively) 
(manuscript in preparation).  
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Discussion 
 
 
This study evaluates the participation of A2A receptors in behavioral and 
neurochemical responses related to morphine addictive effects, including reward and the 
dysphoric effects associated to naloxone precipitated morphine withdrawal. We also 
investigated acute responses of morphine on nociception and locomotion to assure that 
motivational and neurochemical responses observed were not influenced by changes in 
acute morphine effects. Mice lacking A2A receptors exhibit similar acute responses after 
morphine administration compared to WT littermates. However, both rewarding and 
aversive effects associated to morphine abstinence were completely abolished in mice 
lacking the A2A receptors.  
Deletion of A2A receptors did not modify acute effects induced by morphine. A 
hypoalgesic phenotype was previously reported, but the thermal stimulus was stronger 
than that used in the present study (Ledent et al., 1997). Thus, changes in basal 
nociceptive responses in A2A KO mice are not robust when using the tail-immersion test 
at 50ºC, and several studies now suggest that the hypoalgesic phenotype is dependent on 
the intensity of the stimulus used (for review see Ferré et al., 2007). Our data 
demonstrate that A2A receptors do not participate in the acute effects induced by 
morphine. 
Morphine-induced rewarding responses were abolished in A2A KO mice. A2A 
receptors are mainly located in striatal neurons where they interact with multiple 
neurotransmitter systems, being coexpressed with postsynaptic receptors in GABAergic 
neurons (Fink et al., 1992). Adenosine regulates DA transmission through antagonistic 
interactions of  A2A/dopamine D2 receptors (Franco et al., 2000), and this interaction 
also modulates glutamate release and thereby affects the striatal neuronal output (Tozzi 
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et al., 2007). The regulation of A2A receptors on DA transmission is pertinent to the 
behavioral findings of the present study. Hence, the neurotransmitter DA has been 
widely implicated as a key regulator of the pharmacological actions and rewarding 
properties of drugs of abuse (Berridge & Robinson 1998; Spanagel & Weiss 1999; 
Wise, 2004).  In addition, DARPP-32, which plays an obligatory role in dopaminergic 
transmission, was reported to be altered in mice lacking A2A receptors (Svenningsson et 
al., 2000), and a large body of evidence support a key role for DARPP-32 dependent 
signaling in mediating the action of multiple drugs of abuse, including caffeine and 
morphine (Svenningsson et al., 2005). Mu-opioid receptor agonists, such as morphine, 
have been reported to increase DA release preferentially in the NAc by the disinhibition 
of γ-aminobutyric acid neurons (Di Chiara & Imperato 1988; Johnson & North 1992).  
Microdialysis experiments in freely-moving WT and adenosine A2A receptor KO mice 
revealed no difference between genotypes in basal or saline-evoked extracellular DA 
levels in the NAc in comparison to previous reports of hypodopaminergic activity in the 
striatum of KO mice (Dassesse et al., 2001).  Despite producing recognized behavioral 
responses of hyperlocomotion and straub tail, (Rethy et al., 1971; Gupta et al., 1988) 
morphine up to 20 mg/kg failed to increase extracellular DA release in either the core or 
shell of the NAc.  In contrast both genotypes displayed a robust and reliable increase in 
accumbal DA in response to cocaine making clear that these mice do respond to 
dopamimetic agents.  Others have shown morphine-induced DA release in a C57/B6 
mouse strain (Chefer et al., 2003) and the lack of a DA response in the current study 
might be attributable to the outbred background strain of these mice (CD1) as previous 
studies have suggested that differences in the background strain of experimental models 
can result in a variable sensitivity to drugs of abuse (Barbaccia et al., 1981; Shoaib et 
al., 1995; He & Shippenberg 2000; Fadda et al., 2005).  Interestingly the CD1 strain has 
  Castañé et al. 
 19
been previously characterized as ethanol-avoiding (Short et al., 2006).  This suggests 
that the CD1 strain may have a differential sensitivity to drugs of abuse explaining its 
weak response to the neurochemical effects of morphine in the NAc. 
It is known that mu-opioid receptors are responsible for morphine-induced 
motivational responses (Matthes et al., 1996).  Until now, no study has investigated the 
role of A2A receptors related to aversive responses developed during morphine 
withdrawal. Interestingly, our findings demonstrate that the absence of A2A receptors 
impair the aversive responses exhibited during abstinence. As we have shown no 
significant changes in mu-opioid receptor binding in brains from naloxone-precipitated 
withdrawn A2A KO mice (Bailey et al., 2004), and a lack of change in mu-opioid 
receptor binding also in naive A2A KO mice (Bailey et al., 2002), compensatory changes 
in the expression of opioid receptors in A2A KO mice are unlikely to account for the 
absence of dysphoric effects related to abstinence. However, a significant increase in the 
level of mu-opioid receptor-stimulated [35S]GTPγS binding was reported  in the NAc 
but not in other brain structures of morphine abstinent mutant mice (Bailey et al., 2004). 
It is therefore possible that the increase of mu-opioid receptor G-protein activity in the 
NAc might be a compensatory mechanism undertaken to increase levels of extracellular 
DA that are extremely low in A2A KO mice during the morphine withdrawal syndrome. 
This increase in DA neurotransmission, through the enhancement of intracellular 
transduction mechanisms associated with mu-opioid receptor activation, could be 
responsible for the lack of dysphoric effects observed during morphine withdrawal in 
A2A KO mice and could progressively appear as an adaptive process whilst physical 
dependence is developed. 
Motor and motivational responses to opioids have been reported to be closely 
related (Salamone, 1996). In our case, the absence of place preference and place 
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aversion were not dependent on the locomotor impairment of A2A KO mice as these 
animals preserve the motor response to morphine (Fig 1). In a previous study, using a 
similar procedure to induce morphine dependence, we reported an enhancement in the 
physical expression of the morphine withdrawal syndrome in mice lacking A2A 
receptors as revealed by a higher global withdrawal score in KO morphine-dependent 
mice (Berrendero et al., 2003; Bailey et al., 2004). In agreement with these findings, 
pharmacological studies showed that A2A selective adenosine receptor agonists 
decreased the incidence of some morphine withdrawal signs, whereas the administration 
of adenosine antagonists produced opposite responses (Salem & Hope, 1997; Zarrindast 
et al., 1999). In addition, electrophysiological studies have reported that the non-
selective adenosine antagonist caffeine enhances the electrical activity recorded in the 
nucleus paragigantocellularis (Khalili et al., 2001), a brain structure which participates 
in the expression of the somatic expression of opioid withdrawal syndrome (Rasmussen 
& Aghajanian 1989). 
Our results demonstrate a clear dissociation between the mechanisms involved 
in the motivational properties of opiates, which are related to their addictive capacities, 
and the somatic signs of naloxone-precipitated withdrawal syndrome, which reveal the 
physical component of opiate dependence. Thus, adenosine A2A receptors appear to be 
crucial for rewarding and aversive effects of opiates and for the expression of the 
physical opiate dependence, modulating the motivational effects and somatic abstinence 
in opposite directions. Our findings also support the belief that receptors involved in 
addictive behaviors induced by prototypic drugs require activation of A2A adenosine 
receptors, just as it has been shown for ethanol operant self-administration (Arolfo et 
al., 2004). Further, we have also demonstrated that A2A KO mice elicit a decreased rate 
of self-administration and motivation for cocaine and decrease the rewarding effects of 
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nicotine and Δ9-tetrahydrocannabinol (Soria et al., 2004; Castañé et al., 2006; Soria et 
al., 2005). The current findings now show evidence that A2A adenosine receptors are 
also required for the expression of morphine rewarding responses and the negative 
motivational effects related to morphine withdrawal syndrome. We conclude that 
adenosine acting through the A2A adenosine receptors represent a general system for 
modulating addictive behaviors and support the possibility that pharmacological 
manipulation of these receptors may represent a new target in the management of drug 
addiction. 
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Legends of the Figures 
 
Figure 1. Acute locomotor effects induced by morphine in A2A KO and WT mice. 
Locomotor activity was evaluated during 30 min after acute morphine injection (0; 5 
and 10 mg/kg, s.c.). Measurements of (a) ambulatory movements (b) total horizontal 
movements (ambulatory plus minor movements) and (c) vertical movements were 
performed. Data are expressed as mean ± SEM of locomotor activity counts (n = 10 in 
all groups). White columns represent WT mice and black columns represent A2A 
adenosine receptor KO mice.  p < 0.05;  p < 0.01 versus vehicle (Dunnet test). 
 
 
Figure 2. Acute antinociceptive effects induced by morphine in A2A KO and WT 
mice. Antinociceptive responses in the tail-immersion (a) and hot-plate (b and c) tests 
were measured 30 min after morphine administration (0; 5 and 10 mg/kg, s.c.). Results 
are expressed as mean ± SEM of latency time in seconds (n = 10 in all groups).  p < 
0.05;  p < 0.01 versus vehicle (Dunnet test). 
 
Figure 3. Morphine-induced conditioned place preference in A2A KO and WT 
mice. Results are expressed as mean ± S.E.M. of time spent in the drug-paired 
compartment (sec) during the pre-conditioning (white bars) and post-conditioning phase 
(black bars) in WT and KO mice after morphine 5 mg/kg (MOR 5), morphine 10 mg/kg 
(MOR 10) or saline (SAL) administration (SAL WT, n = 22; SAL KO, n = 22; MOR 5 
WT, n = 10; MOR 5 KO, n = 9; MOR 10 WT, n = 12; MOR 10 KO, n = 12).  p < 
0.01 versus pre-conditioning phase (Student paired t-test). 
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Figure 4. Naloxone-induced conditioned place aversion in morphine-dependent 
A2A KO and WT mice. Results are expressed as mean ± S.E.M. of time spent in the 
drug-paired compartment (sec) during the pre-conditioning (white bars) and post-
conditioning phase (black bars) in saline (SAL) and morphine (MOR) treated WT and 
KO mice after saline (SAL), naloxone 0.05 mg/kg (NAL 0.05) or naloxone 0.1 mg/kg 
(NAL 0.1) administration (SAL-SAL WT, n = 11; SAL-SAL KO, n = 13; SAL-NAL 
0.05 WT, n = 12; SAL-NAL 0.05 KO, n = 13; SAL-NAL 0.1 WT, n = 10; SAL-NAL 
0.1 KO, n = 11; MOR-SAL WT, n = 11; MOR-SAL KO, n = 13; MOR-NAL 0.05 WT, 
n = 14; MOR-NAL 0.05 KO, n = 14; MOR-NAL 0.1 WT, n = 14; MOR-NAL 0.1 KO, 
n = 15).  p < 0.01 versus pre-conditioning phase (Student paired t-test). 
 
Figure 5. Effects of the systemic morphine administration on dialysate DA 
concentrations in the NAc of A2A KO and WT mice. Morphine (20 mg/kg, s.c.) did 
not increase DA output in the NAc of WT (vehicle, SAL n = 5; morphine, MOR n = 6) 
and KO mice (vehicle, SAL n = 6; morphine, MOR n = 7) in any dialysis fraction (F8-
F13). Data are percentages of pre-treatment (basal) values and are given as mean + 
SEM values (see methods section for details).  
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Table 1. Two-way ANOVA for acute locomotor and antinociceptive responses induced by morphine in A2A adenosine receptor. 
 
 
 
 Two-way ANOVA with treatment (T) and genotype (G) as factors of variation. See Materials and Methods for details.  
  
 
 Locomotor activity Antinociception 
 Ambulatory Total horizontal Vertical Tail-immersion Hot-plate: Licking Hot-plate: jumping 
 F p  F p  F p  F p  F p  F p  
Treatment F(2.54) = 63.672 0.01 F(2.54) = 35.977 0.01 F(2.53) = 14.704 0.01 F(2.53) = 50.431 0.01 F(2.54) = 9.785 0.01 F(2.54) = 502.15 0.01 
Genotype  F(1.54) = 9.526 0.01 F(1.54) = 17.606 0.05   F(1.53) = 4.523 0.05 F(1.53) = 1.884 n.s. F(1.54) = 0.083 n.s. F(1.54) = 1.164 n.s. 
TxG  F(2.54) = 0.523 n.s.   F(2.54) = 0.587 n.s. F(2.53) = 1.749 n.s. F(2.53) = 0.930 n.s. F(2.54) = 0.519 n.s. F(2.54) = 0.291 n.s. 
Wild-type A2a knockout
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